POMC:W84X変異によるPOMC欠乏症の肥満患者からヒト誘発性多能幹細胞の生成
Katarzyna A Ludwik1, Regina Jahn1, Sabine Jyrch2
1Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Core Unit pluripotent Stem Cells and Organoids, Berlin 13353, Germany.
Stem cell research
|September 3, 2025
まとめ
私たちはPOMC遺伝子変異による 重度の肥満の患者から 人工多能幹細胞 (iPSC) を生み出しました この新しい細胞系は 肥満のメカニズムや 治療の可能性の研究に役立ちます
科学分野:
- 幹細胞生物学
- 遺伝学
- 内分泌学
背景:
- 早期発症した重度の肥満は 重要な代謝経路に影響する遺伝子の変異に起因する可能性があります
- プロオピオメラノコルチン (POMC) 遺伝子変異は肥満の原因として知られています.
- 人間の誘発性多能幹細胞 (iPSC) は,遺伝疾患の研究のモデルを提供します.
研究 の 目的:
- POMC遺伝子変異による肥満の患者から新しいヒト誘発性多能幹細胞 (iPSC) ラインを生成し,特徴づけること.
- POMC欠乏症の分子基盤を調査するための細胞モデルを確立する.
主な方法:
- ホモジゴスなPOMC (W84X) 変異を有する患者の皮膚線維細胞は,iPSCに再プログラムされました.
- 再プログラミングは RNAベースの非統合ベクトルによる 多能性因子を用いた.
- 特徴付けには,形態学,多能性マーカーの発現,カリオタイプの安定性,および差別化の可能性の評価が含まれていた.
主要な成果:
- 生成されたIPSC系はBIHi261-Aと指定され,典型的な幹細胞形態を示し,主要な多能性マーカーを示した.
- BIHi261-Aは培養中に正常なカリオタイプを維持した.
- iPSC系は,3つの生殖層から細胞タイプに成功裏に微分化し,多能性を確認した.
結論:
- BIHi261-A iPSCラインは,POMC関連肥満の患者から得られたよく特徴づけられた細胞モデルです.
- この iPSC ラインは,POMC 欠乏症の病理生理学の研究に貴重なリソースとして役立つ.
- BIHi261-Aは肥満に対する新しい治療戦略の開発と試験を容易にする.
さらに関連する動画
09:11Generation of Induced Pluripotent Stem Cells from Muscular Dystrophy Patients: Efficient Integration-free Reprogramming of Urine Derived Cells
Published on: January 28, 2015
11.4K
12:03Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector
Published on: October 31, 2012
26.8K
関連する概念動画
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
Somatic to iPS Cell Reprogramming
2.3K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.3K
iPS Cell Differentiation
2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
EPS and iPS Cells in Disease Research
2.9K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.9K
